enGene Holdings Inc.
General ticker "ENGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $439.1M (TTM average)
enGene Holdings Inc. does not follow the US Stock Market performance with the rate: -31.5%.
Estimated limits based on current volatility of 1.9%: low 1.83$, high 1.90$
Factors to consider:
- Total employees count: 82 (+43.9%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Manufacturing failures, Labor/talent shortage/retention, Commercialization challenges
- Current price 57.4% below estimated low
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-10-31 to 2027-10-31
- 2025-10-31 to 2026-10-31 estimated range: [4.48$, 11.68$]
- 2026-10-31 to 2027-10-31 estimated range: [3.67$, 9.85$]
Financial Metrics affecting the ENGN estimates:
- Negative: with PPE of -3.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.75 <= 0.75
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: -7.11 < Investing cash flow per share per price, % of -6.31
Short-term ENGN quotes
Long-term ENGN plot with estimates
Financial data
| YTD | 2023-10-31 | 2024-10-31 | 2025-10-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $26.06MM | $62.30MM | $123.17MM |
| Operating Income | $-26.06MM | $-62.30MM | $-123.17MM |
| Non-Operating Income | $-73.84MM | $7.14MM | $5.86MM |
| Interest Expense | $4.95MM | $2.80MM | $2.99MM |
| R&D Expense | $16.46MM | $38.31MM | $94.48MM |
| Income(Loss) | $-99.90MM | $-55.16MM | $-117.30MM |
| Taxes | $0.02MM | $-0.02MM | $0.00MM |
| Net Income(Loss)* | $-99.92MM | $-55.14MM | $-117.30MM |
| Stockholders Equity | $72.49MM | $272.61MM | $167.71MM |
| Assets | $86.96MM | $311.17MM | $221.47MM |
| Operating Cash Flow | $-24.74MM | $-48.28MM | $-99.24MM |
| Capital expenditure | $0.32MM | $0.93MM | $1.49MM |
| Investing Cash Flow | $-0.32MM | $-125.95MM | $-25.14MM |
| Financing Cash Flow | $86.15MM | $265.72MM | $1.52MM |
| Earnings Per Share** | $-4.24 | $-1.24 | $-2.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.